Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2014. The report details a specific share repurchase transaction executed on June 9, 2014, pursuant to shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 625,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,597.50 pence per share; lowest price paid was 1,584.50 pence per share.
- Treasury Holdings (Settled): 497,973,914 shares (9.31% of total issued share capital).
- Treasury Holdings (Including Unsettled): 500,172,414 shares (10.31% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,852,825,510 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 625,000 shares for treasury. Consequently, the percentage of total voting rights held in treasury increased to 10.31% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares held in treasury (497,973,914 settled) against the company's latest capitalization table.
- Confirm the denominator for voting rights calculations is 4,852,825,510 shares (excluding treasury shares).
- Note that the repurchase price range (1,584.50 to 1,597.50 pence) reflects the market price on June 9, 2014.